{"analyses":[{"ciLowerLimit":"0.55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.77","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"Regression, Cox method","pValue":"< 0.0001","pValueComment":"One-sided p-value based on log-rank test stratified by ECOG performance status, geographic region, and prior history of pelvic radiation.","paramType":"Hazard Ratio (HR)","paramValue":"0.65","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.6","spread":"15.6","upperLimit":"21.3","value":"18.7"},{"groupId":"OG001","lowerLimit":"10.7","spread":"10.7","upperLimit":"13.3","value":"11.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"416"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who were lost to follow-up and those who were alive at the date of data cut-off were censored at the date the participant was last known alive, or date of data cut-off, whichever occurred first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Endometrial cancer (EC) received lenvatinib 20 milligrams (mg) orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study","id":"OG000","title":"Lenvatinib 20 mg + Pembrolizumab 200 mg"},{"description":"Participants with EC received either doxorubicin 60 milligrams per square meter (mg/m\\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle. Participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\\^2 doxorubicin, a maximum dose of paclitaxel per standard of care, or until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.","id":"OG001","title":"Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel"}],"paramType":"NUMBER","populationDescription":"Analysis population consisted of ITT population which included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 43 months","title":"OS in All-comer Participants","type":"PRIMARY","unitOfMeasure":"Months"}